Literature DB >> 22938030

EC144 is a potent inhibitor of the heat shock protein 90.

Jiandong Shi1, Ryan Van de Water, Kevin Hong, Ryan B Lamer, Kenneth W Weichert, Cristina M Sandoval, Srinivas R Kasibhatla, Marcus F Boehm, Jianhua Chao, Karen Lundgren, Noelito Timple, Rachel Lough, Gerardo Ibanez, Christina Boykin, Francis J Burrows, Marilyn R Kehry, Theodore J Yun, Erin K Harning, Christine Ambrose, Jeffrey Thompson, Sarah A Bixler, Anthone Dunah, Pamela Snodgrass-Belt, Joseph Arndt, Istvan J Enyedy, Ping Li, Victor S Hong, Andres McKenzie, Marco A Biamonte.   

Abstract

Alkyne 40, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein 90 (Hsp90) and is substantially more potent in vitro and in vivo than the first generation inhibitor 14 (BIIB021) that completed phase II clinical trials. Alkyne 40 is more potent than 14 in an Hsp90α binding assay (IC(50) = 1.1 vs 5.1 nM) as well as in its ability to degrade Her-2 in MCF-7 cells (EC(50) = 14 vs 38 nM). In a mouse model of gastric tumors (N87), 40 stops tumor growth at 5 mg/kg and causes partial tumor regressions at 10 mg/kg (po, qd × 5). Under the same conditions, 14 stops tumor growth only at 120 mg/kg, and does not induce partial regressions. Thus, alkyne 40 is approximately 20-fold more efficacious than 14 in mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22938030     DOI: 10.1021/jm300810x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

Review 1.  A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Authors:  Tony Taldone; Tai Wang; Anna Rodina; Naga Vara Kishore Pillarsetty; Chander S Digwal; Sahil Sharma; Pengrong Yan; Suhasini Joshi; Piyusha P Pagare; Alexander Bolaender; Gail J Roboz; Monica L Guzman; Gabriela Chiosis
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

Review 2.  Adapting Secretory Proteostasis and Function Through the Unfolded Protein Response.

Authors:  Madeline Y Wong; Andrew S DiChiara; Patreece H Suen; Kenny Chen; Ngoc-Duc Doan; Matthew D Shoulders
Journal:  Curr Top Microbiol Immunol       Date:  2018       Impact factor: 4.291

Review 3.  Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.

Authors:  Len Neckers; Brian Blagg; Timothy Haystead; Jane B Trepel; Luke Whitesell; Didier Picard
Journal:  Cell Stress Chaperones       Date:  2018-02-01       Impact factor: 3.667

4.  Synthesis and Evaluation of Small Molecule Disruptors of the Aha1/Hsp90 Complex for the Reduction of Tau Aggregation.

Authors:  Bradley M Keegan; Kevin C Catalfano; Monimoy Banerjee; Brian S J Blagg
Journal:  ACS Med Chem Lett       Date:  2022-04-15       Impact factor: 4.632

Review 5.  The Inflammasome NLR Family Pyrin Domain-Containing Protein 3 (NLRP3) as a Novel Therapeutic Target for Idiopathic Pulmonary Fibrosis.

Authors:  Ruben M L Colunga Biancatelli; Pavel A Solopov; John D Catravas
Journal:  Am J Pathol       Date:  2022-03-26       Impact factor: 5.770

6.  Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.

Authors:  Tony Taldone; Pallav D Patel; Maulik Patel; Hardik J Patel; Christopher E Evans; Anna Rodina; Stefan Ochiana; Smit K Shah; Mohammad Uddin; Daniel Gewirth; Gabriela Chiosis
Journal:  J Med Chem       Date:  2013-08-21       Impact factor: 7.446

Review 7.  Protein chaperones: a composition of matter review (2008 - 2013).

Authors:  Tony Taldone; Hardik J Patel; Alexander Bolaender; Maulik R Patel; Gabriela Chiosis
Journal:  Expert Opin Ther Pat       Date:  2014-05       Impact factor: 6.674

Review 8.  Stressing Out Hsp90 in Neurotoxic Proteinopathies.

Authors:  Carmen Inda; Alexander Bolaender; Tai Wang; Srinivasa R Gandu; John Koren
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 9.  Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future.

Authors:  Daniel T Gewirth
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

10.  Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening.

Authors:  JianMin Jia; XiaoLi Xu; Fang Liu; XiaoKe Guo; MingYe Zhang; MengChen Lu; LiLi Xu; JinLian Wei; Jia Zhu; ShengLie Zhang; ShengMiao Zhang; HaoPeng Sun; QiDong You
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.